- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- FDA approves first single-entity, extended-release hydrocodone drug
- Study: OTC ibuprofen as effective as Rx in treating post-operative pain after having tonsils removed
PARSIPPANY, N.J. — Generic drug maker Watson Labs recalled two lots of a prescription painkiller due to the potential for oversized and overly potent tablets, the company said.
The drug maker announced the recall of hydrocodone bitartrate and acetaminophen tablets in the 10 mg/500 mg strengths based on a customer complaint of tablets that were thicker and darker-colored than the others.
The recalled lots are 519406A and 521759A, and the company said some tablets from the lots may exceed the weight specification and contain higher doses of hydrocodone or acetaminophen.